"Sanjay Gupta, PhD, of Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center will receive $962,000 over three years to investigate drug resistance mechanisms in prostate cancer. The funding is part of the Department of Defense's Idea Award program, that aims to improve quality of life by decreasing the impact of cancer on active duty service members and their communities." 
Something of a letdown to read that Gupta will be looking at Simvastatin and Metformin, two drugs I have been using for almost a decade.
"Gupta will study simvastatin and metformin--two drugs that appear promising in his preliminary studies. Together, the drugs weaken CRPC cells and halt metastasis. Simvastatin works by blocking the rate-limiting enzyme for cholesterol synthesis, called HMG-CoAR (3-hydroxy-3-methylglutaryl-Coenzyme A). Metformin activates AMP kinase (5'-adenosine monophosphate kinase), a so-called "master regulator" of androgen signaling in prostate cancer cells."
"Together with colleagues, Gupta will test whether the enzymes HMG-CoAR and AMP kinase represent novel therapeutic targets for CRPC--particularly CRPC that is already resistant to existing androgen inhibitor drugs. The researchers will transplant drug-resistant CRPC patient samples into mouse models and determine if changing the enzymes' levels via medications offers therapeutic benefits."
In 2014, Gupta published:
"Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer" .
I have been looking through Gupta's papers on PubMed & came across a full-text 2017 review of Apigenin .
My own PCa-Apigenin review was posted two years before , so probably needs updating. It mentions a Gupta paper , but Gupta has a lot of apigenin papers - there are 23 PubMed hits for <Sanjay Gupta "Case Western" apigenin> .